Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
- cagrilintide monotherapy: 0.3, 0.6, 1.2, 2.4, 3.0, 4.5 mg SC once weekly (Phase 2).
- CagriSema: semaglutide 2.4 mg + cagrilintide 2.4 mg SC once weekly (Phase 2 co-formulation).
- Titration schedules vary by protocol; published regimens should not be extrapolated to unapproved use.